OVERVIEW

Chronic Lymphocytic Leukemia: Evolving Treatment Strategies and the Role of the Specialty Pharmacist in Improving Patient Outcomes is organized by Pharmacy Times Continuing Education (PTCE).

Release Date: May 31, 2019
Expiration Date: May 31, 2020

Target Audience:
Specialty Pharmacists and Managed Care Professionals.

Accreditation:
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs)

Activity Overview:
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults, with over 20,000 patients diagnosed annually in the United States. The body of literature has grown tremendously in the past 6 to 12 months, with evidence demonstrating that oral oncolytics have a substantial and evolving role in the treatment paradigm for CLL. Specialty pharmacists are uniquely positioned to manage and counsel patients as well as advise health care professionals about adverse events and novel guideline-recommended targeted options. This presentation will provide information on the current and emerging therapies for patients with CLL, how to incorporate these agents into specific treatment regimens, and the pharmacist’s role in developing patient-centered solutions including adherence strategies, patient self-care management, implications of financial toxicity, and coordination of care.

Educational Objectives:
At the completion of this activity, the participant will be able to:
• Identify disease- and patient-specific prognostic factors that guide selection of therapeutic options for patients with CLL
• Analyze current treatment strategies for CLL based on evidence for efficacy and safety
• Recognize appropriate prevention and management of therapy-induced adverse effects
• Explain the role of the pharmacist in improving adherence and disease outcomes in patients receiving CLL therapy